Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 6/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 5/20 | 0.45 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.42 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21943638 | 0.92 | BRAF (0.54) | BRAFPOLBKDM4ECSF1RGAA | |
| SCHEMBL21943450 | 0.88 | BRAF (0.51) | BRAFPOLBKDM4EGAAKIT | |
| SCHEMBL21943519 | 0.87 | CSF1R (0.54) | BRAFPOLBKDM4ECSF1RKIT | |
| SCHEMBL21943069 | 0.87 | KDR (0.51) | BRAFPOLBKDM4EKITPDGFRB | |
| SCHEMBL21943658 | 0.85 | PIKFYVE (0.59) | BRAFPOLBCSF1RGAAKIT | |
| SCHEMBL21943452 | 0.85 | KDR (0.47) | BRAFPOLBKDM4ECSF1RKIT | |
| SCHEMBL21943451 | 0.84 | KDR (0.58) | BRAFPOLBKDM4ECSF1RKIT | |
| SCHEMBL22024557 | 0.83 | PIKFYVE (0.61) | BRAFPOLBKDM4ECSF1RKIT | |
| SCHEMBL21943735 | 0.81 | BRAF (0.51) | BRAFPOLBKDM4ECSF1RKIT | |
| SCHEMBL22065428 | 0.80 | POLB (0.58) | BRAFPOLBKDM4ECSF1RKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319322-B2 | Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof | XIAMEN UNIVERSITY (CN) | 2022-05-03 | — | — | US | disclosed |
| US-20200123162-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | XIAMEN UNIVERSITY (CN) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123162-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | CYP4A11, CYP2D6, CYP3A43 | BRAF 95/4885POLB 4357/4885KDM4E 229/4885 |
| US-11319322-B2 | Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof | CYP4A11, CYP2D6, CYP3A43 | BRAF 95/4885POLB 4357/4885KDM4E 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.